Pasithea Therapeutics Corp.
KTTA
$0.57
-$0.03-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.99% | -0.82% | 91.32% | 23.12% | 4.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.92% | 32.51% | 86.89% | 3.51% | -3.40% |
| Operating Income | -49.92% | -32.51% | -86.89% | -3.51% | 3.40% |
| Income Before Tax | -41.92% | 19.47% | -218.18% | -1.25% | 3.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.92% | 19.47% | -218.18% | -1.25% | 3.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.92% | 19.47% | -218.18% | -1.25% | 3.88% |
| EBIT | -49.92% | -32.51% | -86.89% | -3.51% | 3.40% |
| EBITDA | -52.22% | -34.15% | -91.60% | -3.03% | 3.52% |
| EPS Basic | 75.06% | 92.68% | 68.75% | 85.80% | 82.22% |
| Normalized Basic EPS | 75.05% | 92.68% | 81.62% | 85.80% | 82.22% |
| EPS Diluted | 75.06% | 92.68% | 68.75% | 85.80% | 82.22% |
| Normalized Diluted EPS | 75.05% | 92.68% | 81.62% | 85.80% | 82.22% |
| Average Basic Shares Outstanding | 469.02% | 1,000.66% | 918.07% | 612.92% | 440.72% |
| Average Diluted Shares Outstanding | 469.02% | 1,000.66% | 918.07% | 612.92% | 440.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |